NASDAQ · GALTHealthcarePharmaceuticals

Galectin Therapeutics news

$3.91−0.51%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Galectin Therapeutics

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

GlobeNewswire Inc.May 27, 8:00 AM ET▲ Positive

The company presented statistically significant clinical trial results showing belapectin's efficacy in reducing varices development and improving liver stiffness markers in MASH cirrhosis patients. The poster was designated a TOP Poster at a major medical conference, and results were published in a flagship journal, validating the drug's disease-modifying potential in an indication with no approved therapies.

Also mentions GALT

Articles that tag GALT but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology